.jpg)
The recent judicial developments in the Salus Pharmaceuticals matter mark an important step towards greater clarity in pharmaceutical regulatory matters.
The Himachal Pradesh High Court, Shimla, in its judgment dated 7 May 2026, examined the regulatory and procedural aspects of the matter and quashed the proceedings against the petitioners.
The matter subsequently reached the Hon’ble Supreme Court of India, which on 15 September 2026 dismissed the Union of India’s SLP, leaving the High Court judgment undisturbed in the particular case.
For the pharmaceutical industry, the development provides an opportunity to further strengthen regulatory clarity, coordination and understanding of respective responsibilities.
The industry sincerely appreciates the important role of CDSCO and State Drug Regulatory Authorities in maintaining the quality, safety and efficacy of medicines. Continued cooperation between regulators and industry can help create an environment that supports both strong compliance and smooth regulatory functioning.